psma 11

PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.

JR11-PEG3-DOTA-PSMA-03 (Compound 2) is a RDC-related compound consisting of the chelator DOTA, the JR11 peptide (an SSTR2 antagonist), and a PSMA ligand. It binds to SSTR2 and PSMA with IC50 values of 94.0 nM and 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [68Ga] and the [68Ga]-labeled version is utilized in diagnostic studies of neuroendocrine-differentiated prostate cancer.

JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound comprising the chelator HBED-CC, the JR11 peptide (an SSTR2 antagonist), and a PSMA ligand. It binds to SSTR2 and PSMA with IC50 values of 59.2 nM and 57.0 nM, respectively. This compound can be radiolabeled with [68Ga], and the [68Ga]-labeled JR11-PEG3-HBED-CC-PSMA-03 is utilized in diagnostic research for neuroendocrine-differentiated prostate cancer.